Medidata Launches Bundled Solutions To Support Oncology And Vaccine Trials, Accelerating Study Design And Execution

NEW YORK, Nov 1 (Bernama) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety.

"Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety," said Joseph Schmidt, chief operating officer, Medidata. "By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata’s vast experience and expertise in these two important therapeutic areas. These bundles are designed to help customers navigate the complicated stages of these studies while advancing life-saving treatments."